SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer
Description of Invention:
Steroid hormones have been implicated in playing a fundamental role in the pathogenesis of prostate cancer. Polymorphisms in the genes that code for enzymes or hormones involved in androgen regulatory pathway are proposed to influence an individual's risk for developing prostate cancer. Since many membrane transporters are modulators of steroid hormones absorption and tissue distribution, genetic polymorphisms in genes encoding these transporters may account for the risk of prostate cancer and the predicting of survival. The OATP1B3 (formerly OATP8) steroid uptake transporter is overexpressed in prostate cancer, and polymorphisms in SLCO1B3 have been associated with altered testosterone uptake, and also an increased prostate cancer risk.
This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient. This genetic profiling result has profound clinical applications in diagnosis for each individual patient and ultimate treatment regimen. Specifically, the inventors have provided a correlation between clinical outcome of SLCOlB3 genotype with median survival of androgen independent prostate cancer. They have also shown that the genotype is predictive of testosterone uptake through the OATP1B3 transporter, and this information is useful to inform clinical decisions regarding antiandrogen therapy.
Advantages and Applications:
SLCO1B3 genotyping can be used in combination on a gene chip with several polymorphisms known to predict survival of prostate cancer patients. Thus the OATP1B3 polymorphism would be one genetic marker in a series of other markers that would be used to inform clinical decisions.
SLCO1B3 upregulation can be used as a prognostic tool.
Development Status:
Initial experiments have been performed with clinical samples from patients with prostate cancer.
Patent Status:
DHHS Reference No. E-083-2007/0 --
U.S. Provisional Application No. 60/879,503 filed 08 Jan 2007
Licensing Status: Available for exclusive and non-exclusive licensing.
Collaborative Research Opportunity:
The National Cancer Institute's Medical Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of the SLCO1B3 genotyping to inform clinical decisions regarding drug treatment, or prognosis of prostate cancer. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro Cancer -Diagnostics-In Vivo Cancer -Diagnostics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
